| Table 2. Different Products and Comparison between GLP1RAs. | ||||||
| Drug | Brand Name | Via Adm | Dose | Half- Life T | Half- Life T | Approved |
|---|---|---|---|---|---|---|
| Dulaglutide | Trulicity | Subcutaneous | 0.75, 1.5 | 5 days | once/week | 2014 |
| Semaglutide | Ozempic Rybelsus |
Subcutaneous Oral |
0.25, 1mg 3,7,14 mg |
1 week 1 week |
once/week once daily |
2017 |
| Liraglutide | Victoza Saxenda |
Subcutaneous Subcutaneous |
0.6,1.8mg 6mg |
13h 3 days |
once daily twice/week |
2010 |
| Exenatide ER | Bydureon BC Byetta |
Subcutaneous Subcutaneous |
2, 5,10µg 5,10µg |
1 week 3h |
once/week once daily |
2005 |
| Tirzepatide | Mounjaro Zepbound |
Subcutaneous Subcutaneous |
5mg 5,10,15mg |
5 days 5 days |
once/week once/week |
2022 2023 |
From: Kalra S, Bhattacharya S, Kapoor N. Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists. Diabetes Ther. 2021;12:2133-47.